- Global Pharma News & Resources

Sensyne Health and NHS Greater Glasgow and Clyde sign data access agreement

Oxford, U.K. 1 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a non-exclusive data sharing agreement with NHS Greater Glasgow and Clyde (“NHSGGC”) giving Sensyne access to three separate anonymised patient data sets in three specific disease areas including cardiovascular disease. 

 The anonymised patient data will be used by Sensyne to undertake medical research using Clinical AI, improve pharmaceutical development and help deliver better patient care.

 NHSGGC is one of 14 regional NHS Boards in Scotland. It serves a population of 1.14 million and employs around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK including 35 Hospitals of different types.

 The agreement falls under the Glasgow Safe Haven partnership between NHS Greater Glasgow and Clyde and the University of Glasgow, designed to provide secure access to NHS and other health datasets derived from diverse sources across the health service. The Glasgow Safe Haven is accredited by the Scottish Government as an accredited Safe Haven, and is one of four regional Safe Havens across Scotland. By enabling researchers to link data from different sources, Safe Havens encourage data-driven health research to improve health services, design better treatments, and to create innovative new health products to support better health in Scotland.

 Prof Julie Brittenden, Director of Research and Innovation, NHS Greater Glasgow and Clyde, said:

“We are pleased to collaborate with Sensyne on data-driven approaches which aim to ultimately improve early diagnosis and treatment of various illnesses, including cardiovascular disease. The project will use anonymised patient data within the secure Glasgow Safehaven to test Sensyne’s machine learning models. This is one of many of our collaborations with industry to improve research and development in order to benefit our patients in future.”

 Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“We are delighted to be working with one of the largest NHS Boards in Scotland on data analysis to improve patient care and accelerate medical research. Adding this data sharing agreement to our Strategic Research Agreements expands our access to anonymised patient data to now cover 3.9 million patients.”

Editor Details

Related Links

Last Updated: 01-Oct-2020